Get the Stockscreener App
0.621
7.81%
0.045
Pre-market:
.66
0.039
+6.28%
Genprex Inc stock is traded at $0.621, with a volume of 760.28K.
It is up +7.81% in the last 24 hours and down -3.97% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
See More
Previous Close:
$0.576
Open:
$0.6064
24h Volume:
760.28K
Relative Volume:
1.23
Market Cap:
$6.79M
Revenue:
-
Net Income/Loss:
$-16.73M
P/E Ratio:
-0.0407
EPS:
-15.2598
Net Cash Flow:
$-14.29M
1W Performance:
+22.97%
1M Performance:
-3.97%
6M Performance:
-67.14%
1Y Performance:
-95.23%
1-Day Range:
$0.58
$0.7092
1-Week Range:
$0.4858
$0.7092
52-Week Range:
$0.4229
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.621 | 5.67M | 0 | -16.73M | -14.29M | -15.26 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex (GNPX) Hovers Near Support After Modest Gain, Consolidation Pattern EmergesGamma Squeeze - dars.gov.et
GNPX Q1 2026 Earnings: Net Loss of $0.64 Per Share as Stock Climbs 5.03%Forward Guidance Trends - dars.gov.et
Genprex | 8-K: Current report - Moomoo
GNPX Should I Buy - Intellectia AI
Enterprise value to EBIT forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Price to sales forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Price to book forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Enterprise value to revenue forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Genprex Inc Actuals & Estimates (NASDAQ:GNPX) - TradingView
Genprex’s Reqorsa combo secures Canadian patent for lung cancer - Yahoo Finance
GNPX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Genprex receives Canadian patent allowance for cancer therapy combination - Investing.com UK
Genprex, Inc. Files SEC Form 8-K: Company Details, Nasdaq Listing, and Key Corporate Information (June 22, 2026) - Minichart
Genprex (GNPX) Secures New Patent for Reqorsa Gene Therapy - GuruFocus
Form 8K Genprex Inc For: 22 June - Investing.com UK
Genprex Secures Canadian Patent for Reqorsa Lung Cancer Therapy - TipRanks
Form 8K Genprex Inc For: 22 June By Investing.com - Investing.com South Africa
Genprex receives Canadian patent allowance for cancer therapy combination By Investing.com - Investing.com South Africa
Genprex (NASDAQ: GNPX) secures Canadian patent for REQORSA lung cancer combinations - Stock Titan
Genprex Receives Notice of Allowance from the Canadian Intellectual Property Office for Patent Covering Reqorsa Gene Therapy Combination with PD-1 or PD-L1 Antibodies to Treat Cancer - marketscreener.com
Genprex Inc (GNPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Genprex Shareholders Approve Expanded Equity Plan, Reverse Split - The Globe and Mail
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Genprex (NASDAQ: GNPX) OKs equity plan and reverse split range - Stock Titan
Genprex Inc (GNPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genprex Inc (GNPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genprex Inc (GNPX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genprex Inc (GNPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genprex Inc (GNPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genprex Inc (GNPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Genprex Inc (GNPX) Institutional Confidence - TradingKey
Genprex Inc (GNPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Genprex to Participate at BIO International Convention 2026 - Yahoo Finance
Genprex heads to BIO 2026 for one-on-one biotech meetings - Stock Titan
Genprex Faces Nasdaq Delisting Notice, Plans Compliance Steps - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GNPX Q1 2026 Earnings: Continued Losses as Clinical-Stage Biotech Focuses on Pipeline ProgressEarnings Miss Streak - newsline.com
Genprex, Inc. Files Form 8-K With Nasdaq Listing and Company Information – June 2026 - Minichart
Genprex faces potential delisting from Nasdaq after bid price rule violation - Investing.com UK
Genprex faces potential delisting from Nasdaq after bid price rule violation By Investing.com - Investing.com South Africa
Genprex Received Notice of Delisting - TradingView
Genprex (NASDAQ: GNPX) confronts Nasdaq delisting risk after sub-$1 bid price - Stock Titan
Genprex Inc. (GNPX) Edges Higher Amid Low-Volume Consolidation Near Key Support LevelsMid Cap Momentum - newsline.com
Genprex Inc. (GNPX) Edges Higher on Modest Volume, Faces Key Resistance at $0.68MA Cross Alert - newsline.com
Genprex Q1 2026 Earnings: Net Loss of $0.64 Per Share as Clinical-Stage Operations ContinueEarnings Surprise Report - newsline.com
Genprex (GNPX) files shelf registration to sell up to $250M in securities - Stock Titan
Genprex Files $250M Mixed Securities Shelf - Intellectia AI
GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill
GNPX Q1 2026 Earnings: Net Loss Widens as Clinical-Stage Biotech Advances PipelineCash Flow Report - newsline.com
Genprex trades under $1 as ASCO results land - Bez Kabli
Genprex (GNPX) Q1 2026 Earnings: Net Loss Per Share Reflects Preclinical Investment as Gene Therapy Pipeline AdvancesPost-Announcement Reaction - dars.gov.et
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genprex Inc Stock (GNPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LONGNECKER BRENT M | Director |
Apr 14 '26 |
Sale |
1.23 |
8 |
10 |
9,157 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):